Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Little is known of the changes in human immunodeficiency virus type 1 (HIV-1)-specific effector cytotoxic T lymphocytes (CTL) after potent antiretroviral therapy. Using HLA/peptide tetrameric complexes, we show that after starting treatment, there are early rapid fluctuations in the HIV-1-specific CTL response which last 1 to 2 weeks. These fluctuations are followed by an exponential decay (median half-life, 45 days) of HIV-1-specific CTL which continues while viremia remains undetectable. These data have implications for the immunological control of drug-resistant virus.


Journal article


Journal of virology

Publication Date





797 - 800


Institute of Molecular Medicine, Nuffield Department of Medicine, Oxford OX3 9DS, United Kingdom.


T-Lymphocytes, Cytotoxic, Humans, HIV-1, Acquired Immunodeficiency Syndrome, NAD+ Nucleosidase, ADP-ribosyl Cyclase, Membrane Glycoproteins, Antigens, Differentiation, Antigens, CD, Anti-HIV Agents, Drug Therapy, Combination, Antigens, CD38